AKR1B10表达与乳腺癌新辅助化疗的关系

Relationship between AKR1B10 and adjuvant chemotherapy in breast cancer

目的检测AKR1B10在乳腺癌新辅助化疗前后的表达情况,分析其表达水平与新辅助化疗疗效的相关性,探讨AKR1B10蛋白是否与阿霉素类化疗药物耐药性相关,评价AKR1B10是否可以作为乳腺癌个体化化疗方案制定的预测指标。方法回顾性分析在郴州市第一人民医院确诊为乳腺癌并接受阿霉素类药物新辅助化疗的71例乳腺癌患者的临床资料。免疫组化检测新辅助化疗前、后AKR1B10蛋白的表达情况。对比分析AKR1B10与乳腺患者临床病理资料、新辅助化疗疗效的关系,MTT法检测阿霉素类药物处理对MCF-7/Vector和MCF-7/AKR1B10细胞增殖的抑制率。结果 (1)在71例乳腺癌患者新辅助化疗前组织样本中,AKR1B10的阳性表达率达到90.1%。化疗前AKR1B10的表达水平与肿块大小、淋巴结转移存在相关性(P<0.05),与年龄、远处转移之间不存在相关性(P>0.05);(2)盐酸吡柔比星对稳定表达AKR1B10的乳腺癌细胞系MCF-7/AKR1B10与对照组细胞增殖的抑制作用无显著差异。结论乳腺癌患者的AKR1B10表达水平与肿瘤大小、淋巴结转移存在相关性,与乳腺癌患者接受阿霉素类药物新辅助化疗的疗效之间无相关性。

Objective To investigate the expression of AKR1B10 in breast cancer, and ana- lyze the relationship between the expression of AKR1B10 and therapeutic effectiveness of adju- vant chemotherapy, or chemotherapy-resistant of adriamycin in breast cancer treatment. To e- valuate whether AKR1B10 can be used as a predictor for tailored individualized chemotherapy for breast cancer. Methods Seventy-one patients with breast cancer who received neoadjuvant chemotherapy in the First People＇ s Hospital of Chenzhou were collected. Seventy-one paired tissues from the breast cancer patients were collected before and after neoadjuvant chemothera- py. The expression of AKR1B10 in the tissues was determined by immunohistochemistry. The relationship between AKR1B10 expression levels and clinical pathological characters including the therapeutic effectiveness of neoadjuvant chemotherapy were analyzed by SPSS 18.0 soft- ware. The MCF-7/AKR1B10 cell with the expression of AKR1B10 was established by gene transfection. The cellular proliferation inhibition rates of MCF-7/AKR1B10 cell and MCF-7/ vector cell treated by different concentrations of Pirarubicin （THP） were measured by MTF. Results The positive rate of AKR1B10 expression was 90. 1% in 71 patients with breast canc- er. There were positive correlations between the expression levels of AKR1B10 before chemo- therapy and tumor size or lymph node metastasis （P 〈 0. 05 ）. There was no correlation between the expression level of AKR1B10 before neoadjuvant chemotherapy and neoadjuvant chemother- apy （P 〉0. 05）. The cell proliferation between MCF-7/AKR1B10 cells with AKR1BIO ex- pression and MCF-7/vector without AKR1B10 was not significantly different after THP treat- ment. Conclusion There is positive correlation between AKR1B10 expression and tumor size, lymph node metastasis in the patients of breast cancer, but there is no correlation between the expression level of AKR1B10 before neoadjuvant chemotherapy and therapeutic effectiveness.